Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + ezetimibe + acetylsalicylic acid
- Development stage
- Preclinical
- Lead developer
- Midas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rosuvastatin + ezetimibe + acetylsalicylic acid is a triple fixed-dose combination (FDC) small molecule therapy developed by Midas Pharma for the treatment of dyslipidemia. The product combines three established agents: rosuvastatin, an HMG-CoA reductase inhibitor that lowers LDL cholesterol by inhibiting hepatic cholesterol synthesis; ezetimibe, which inhibits the NPC1L1 transporter to reduce intestinal cholesterol absorption; and acetylsalicylic acid (aspirin), which provides antiplatelet effects via cyclooxygenase inhibition. This combination is designed as a substitution therapy to improve patient adherence and reduce pill burden in individuals already receiving these components as separate or dual-combination treatments. It is available in multiple dose strengths to allow for tailored lipid management and cardiovascular risk reduction.
- Other names
- rosuvastatin + ezetimibe + ASArosuvastatin + ezetimibe + aspirin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PGHS-1 (Prostaglandin G/H Synthase 1)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on rosuvastatin + ezetimibe + acetylsalicylic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + ezetimibe + acetylsalicylic acid.